Angelman Syndrome Clinical Trial
Official title:
A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol
The purpose of the study is to assess the safety and tolerability of oral OV101 (gaboxadol) in adult and adolescent subjects with Angelman syndrome. In addition, several exploratory efficacy outcome measures will be investigated.
Two dosing schedules of OV101 (gaboxadol) giving as once daily or twice daily dose will be assessed against placebo. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05293184 -
The Global Angelman Syndrome Registry
|
||
Completed |
NCT00004351 -
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
|
N/A | |
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT06229769 -
Natural History Study for Patients With Angelman Syndrome
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT03235037 -
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome
|
N/A | |
Recruiting |
NCT05100810 -
Angelman Syndrome Natural History Study-FAST UK
|
||
Completed |
NCT03644693 -
Nutritional Formulation for Angelman Syndrome
|
N/A | |
Completed |
NCT03358823 -
Study on the Brain Network of Angelman Syndrome
|
||
Recruiting |
NCT06337383 -
Study of the Prevalence of Autistic Traits in Angelman Syndrome
|
||
Recruiting |
NCT05945576 -
IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
|
||
Completed |
NCT02670694 -
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
|
N/A | |
Recruiting |
NCT04768803 -
Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
|
||
Recruiting |
NCT05630066 -
Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
|
Phase 2 | |
Completed |
NCT00348933 -
Dietary Supplements for the Treatment of Angelman Syndrome
|
N/A | |
Recruiting |
NCT05011851 -
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
|
Phase 2 | |
Terminated |
NCT03882918 -
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
|
Phase 3 | |
Completed |
NCT02056665 -
Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome
|
Phase 2 | |
Completed |
NCT01281475 -
A Trial of Levodopa in Angelman Syndrome
|
Phase 2/Phase 3 |